{"id":"W4366280595","doi":"10.1038/s41467-023-37648-w","title":"Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia","year":2023,"lang":"en","type":"article","venue":"Nature Communications","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"Deutsche Forschungsgemeinschaft; F. Hoffmann-La Roche","keywords":"Venetoclax; Obinutuzumab; Chlorambucil; Chronic lymphocytic leukemia; Medicine; Internal medicine; Oncology; Minimal residual disease; Hazard ratio; Bendamustine; Clinical endpoint; Leukemia; Gastroenterology; Randomized controlled trial; Chemotherapy; Confidence interval; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001979187,0.0002648098,0.0007937922,0.0002904941,0.0002489886,0.0005709045,0.0002423675,0.0005078534,0.002489112],"category_scores_gemma":[0.001501515,0.0001847536,0.000775227,0.0004071452,0.000330387,0.0002967425,0.0002396542,0.0007341271,0.0002794397],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004750972,"about_ca_system_score_gemma":0.00037711,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005362475,"about_ca_topic_score_gemma":0.0007657456,"domain_scores_codex":[0.9992188,0.0004511853,0.00002881952,0.0001211153,0.0000755524,0.0001045597],"domain_scores_gemma":[0.9988605,0.0004263897,0.000360626,0.00008952736,0.0000846379,0.0001782955],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7296987,0.004940211,0.1345367,0.0004145026,0.002313653,0.0001982936,0.0002618013,0.002448512,0.06725704,0.0001615115,0.002075823,0.05569312],"study_design_scores_gemma":[0.03738323,0.09268293,0.8477924,0.00006915078,0.002941425,0.0003248408,0.0002579998,0.004296754,0.009877372,0.0005146734,0.003774378,0.00008488148],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9978473,0.0006080208,0.0001782819,0.00003737034,0.000009131291,0.00005565531,0.0009929539,0.000008148849,0.0002631388],"genre_scores_gemma":[0.9964499,0.0001488911,0.0002367567,0.0001016736,0.00001518387,0.0001293469,0.002495917,0.000005864452,0.0004162922],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002489112,"threshold_uncertainty_score":0.01046705,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04807670329651975,"score_gpt":0.3432482560445208,"score_spread":0.2951715527480011,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}